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Abstract
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality in American
women. Normal ovarian physiology is intricately connected to small GTP binding proteins of
the Ras superfamily (Ras, Rho, Rab, Arf, and Ran) which govern processes such as signal
transduction, cell proliferation, cell motility, and vesicle transport. We hypothesized that
common germline variation in genes encoding small GTPases is associated with EOC risk.
We investigated 322 variants in 88 small GTPase genes in germline DNA of 18,736 EOC
patients and 26,138 controls of European ancestry using a custom genotype array and
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logistic regression fitting log-additive models. Functional annotation was used to identify bio-
features and expression quantitative trait loci that intersect with risk variants. One variant,
ARHGEF10L (Rho guanine nucleotide exchange factor 10 like) rs2256787, was associated
with increased endometrioid EOC risk (OR = 1.33, p = 4.46 x 10−6). Other variants of interest
included another in ARHGEF10L, rs10788679, which was associated with invasive serous
EOC risk (OR = 1.07, p = 0.00026) and two variants in AKAP6 (A-kinase anchoring protein 6)
which were associated with risk of invasive EOC (rs1955513, OR = 0.90, p = 0.00033;
rs927062, OR = 0.94, p = 0.00059). Functional annotation revealed that the two ARHGEF10L
variants were located in super-enhancer regions and that AKAP6 rs927062 was associated
with expression of GTPase gene ARHGAP5 (Rho GTPase activating protein 5). Inherited var-
iants in ARHGEF10L and AKAP6, with potential transcriptional regulatory function and asso-
ciation with EOC risk, warrant investigation in independent EOC study populations.
Introduction
In 2017, in the United States, more than 21,000 women were expected to be diagnosed with
epithelial ovarian cancer (EOC), and more than 14,000 women were predicted to die from the
disease.[1] EOC is heterogeneous and therefore classified into major histological subtypes of
invasive disease—serous, endometrioid, clear cell, and mucinous–and two histological sub-
types of borderline disease–serous and mucinous. These histological subtypes have differences
in genetic and epidemiologic risk factors, molecular events during oncogenesis, response to
chemotherapy, and prognosis.[2]
Approximately 20% of the familial component of EOC risk is attributable to high-to-inter-
mediate risk gene mutations.[3] In European populations, genome-wide association studies
(GWAS) have identified more than 30 EOC susceptibility alleles, as reviewed previously.[4]
Known common genetic variants explain 3.9% of the inherited component of EOC risk, and
additional susceptibility loci are likely to exist, particularly for the less common, non-serous
histological subtypes.
Normal ovarian physiology is intricately connected to tightly regulated small GTP binding
proteins of the Ras superfamily (Ras, Rho, Rab, Ral, Arf, and Ran) which regulate key cellular
processes such as signal transduction, cell proliferation, cell motility, and vesicle transport.[5]
These proteins function in a highly coordinated manner through signaling networks and feed-
back loops within and among the small GTPase subfamilies.[6] The Rab and Ral GTPases are
thought to function in membrane trafficking in exocyst assembly and vesicle-tethering pro-
cesses;[7, 8] Rho-related proteins function to integrate extracellular signals with specific targets
regulating cell morphology, cell aggregation, tissue polarity, cell motility and cytokinesis.[5]
Ras family genes cycle between their inactive GDP forms in the cytoplasm and the active GTP-
bound forms on the plasma membrane and are associated with signaling pathways contribut-
ing to normal and aberrant cell growth.[9]
As regulation of the RAS signal transduction pathway involves a highly complex, highly
polymorphic machinery of genes, we conducted a large-scale candidate pathway association
study, hypothesizing that variation in small GTPase genes is associated with EOC risk.
Materials and methods
Variant selection
RAS pathway genes were selected based on the Cancer Genome Anatomy Project and review
of the published literature (www.pubmed.gov). Within 115 candidate genes, 6103 single
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nucleotide polymorphism (SNPs) were interrogated in early GWAS analysis of 7931 EOC
patients and 9206 controls;[10] 339 SNPs in 88 of these genes showed nominal evidence of
association with risk of EOC or of serous EOC (p<0.05 using all participants or North Ameri-
can participants only)[10] and were targeted in the present analysis (S1 Table).
Study participants and genotyping
We studied 18,736 EOC patients (10,316 of serous histology) and 26,138 controls who partici-
pated in Ovarian Cancer Association Consortium studies; all participants were of European
ancestry.[11] This included participants from the GWAS which was used for variant selection
(described above)[10] and an additional 10,243 patients and 16,932 controls. Genotyping used
a custom Illumina Infinium array. [11] SNPs were excluded according to the following criteria:
no genotype call; monomorphism; call rate less than 95% and minor allele frequency> 0.05 or
call rate less than 99% with minor allele frequency< 0.05; evidence of deviation of genotype
frequencies from Hardy-Weinberg equilibrium (p< 10−7); greater than 2% discordance in
duplicate pairs. Overall, 322 small GTPase gene SNPs were genotyped and passed QC; num-
bers of participants with data for each SNP vary, as some DNA samples failed QC for particular
SNPs. This study was reviewed and approved by the Mayo Clinic Institutional Review Board
as protocol 1367–05.
Genetic association
We followed STREGA guidelines for genetic association studies.[12] Unconditional logistic
regression treating the number of minor alleles carried as an ordinal variable (log-additive model)
was used to evaluate the association between each SNP and EOC risk adjusted for age, study site,
and principal components to account for residual differences in European ancestry. Six series of
analyses were conducted considering the following groups: all invasive EOC combined, each of
the four main invasive histological subtypes (serous, endometrioid, clear cell and mucinous), and
all borderline tumors combined. No corrections were made for multiple testing.
Functional annotation
For SNPs of interest, dbSUPER [13] and Haploreg v4.1[14] were used to evaluate publicly
available data for variant overlap with human super-enhancers,[15] known expression quanti-
tative trait loci (eQTL), GWAS hits, and other regulatory marks. In addition, we assessed cor-
relations between germline genotype with tumor expression levels (eQTL analysis) using 312
Mayo Clinic patients (226 serous, 54 endometrioid, 22 clear cell, 5 mucinous, and 5 of other
histological subtypes). Expression data were obtained using fresh frozen tumor RNA and Agi-
lent whole human genome 4×44 expression arrays and were analyzed in the form of log ratios
of signals from individual tumors compared to signals from a reference mix of 106 tumor sam-
ples[16, 17] versus signals from a reference mix of 106 tumor samples[16, 17]. Expression lev-
els for minor allele carriers versus non-carriers were compared using the Wilcoxon rank sum
statistic.
Results and discussion
Demographic and clinical characteristics of the study sample (18,736 EOC patients and 26,138
controls) have been described previously.[11] In brief, compared to controls, patients were
older, attained menarche at older ages, and had higher body mass index. As expected, most
tumors (57.6%) were of serous histology with 14.2% endometrioid, 7.1% clear cell, 6.5%
mucinous, and 14.6% other/unknown.
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From among 322 SNPs in 88 RAS pathway small GTPase genes, we observed that 99 SNPs
in 43 genes were nominally associated with EOC risk (p<0.05) (S2 Table). These associations
were from six separate analyses that evaluated all patients with invasive disease, patients with
one of the four main invasive histological subtypes, serous [n = 8,372], endometrioid
[n = 2,068], clear cell [n = 1,025] and mucinous [n = 943], as well as patients with borderline
tumors.
In ARHGEF10L, which encodes the Rho guanine nucleotide exchange factor 10-like pro-
tein, SNP rs2256787 was associated with invasive endometrioid EOC risk (OR = 1.33, 95% CI:
1.18–1.50, p = 4.5x10-6) (Table 1). (Fig 1) shows the ORs and 95% CIs associated with the G
allele at this SNP overall and by contributing study.
Three other variants were associated at p-value<10−4 (Table 1, S1, S2 and S3 Figs).
rs10788679 in an intron of ARHGEF10Lwas associated with risk of invasive serous EOC (OR =
1.07, 95% CI: 1.03–1.11, p = 2.6x10-4;); ARHGEF10L SNPs rs2256787 and rs10788679 are inde-
pendent (r2 = 0.02, 1000 Genomes Project EUR). In addition, rs1955513 was most strongly asso-
ciated with all invasive EOC risk (OR = 0.90, 95% CI: 0.85–0.95, p = 3.3x10-4). This variant lies
in an intron of A-kinase (PRKA) anchor protein 6 (AKAP6). Another variant in AKAP6, intro-
nic SNP rs927062, was also associated with all invasive EOC risk (p = 5.9x10-4); AKAP6SNPs
rs1955513 and rs927062 are in modest linkage disequilibrium (r2 = 0.15, 1000 Genomes Project
EUR).
We investigated whether the four variants of interest, rs2256787, rs10788679, rs1955513,
rs927062, which are all intronic, alter expression of their proximal GTPases, or coincide with
regulatory marks that may affect expression (Table 1). In publicly available databases,[13, 14]
the ARHGEF10L SNPs rs2256787and rs10788679 coincide with a human ovary super-
enhancer, a region of the genome with unusually strong enrichment for the binding of
Table 1. Association of variants in small GTPase genes with epithelial ovarian cancer risk (p-value<10−4) and functional annotation.
Genetic Association Functional Annotation
Gene SNP Chr:Position Alleles MAF Histology OR
(95%
CI)
P-
value
Conserved
site
eQTL Tissues with
enhancer histone
mark
Tissues
with
DNAse
site
In super-
enhancer
ARHGEF10L rs2256787 1:17,765,403 A/C 0.07 Endometrioid 1.33
(1.18–
1.50)
4.5 x
10−6
No No ESC, ESDR, IPSC,
FAT, STRM, BRST,
BRN, SKIN, VAS,
LIV, GI, HRT,
MUS, LNG, OVRY,
PANC
None Yes
rs10788679 1:17,789,549 A/G 0.42 Serous 1.07
(1.03–
1.11)
2.6 x
10−4
No No None None Yes
AKAP6 rs1955513 14:32,245,693 C/A 0.07 All invasive 0.90
(0.85–
0.95)
3.3 x
10−4
Yes No FAT, SKIN, VAS,
BRN, MUS, GI,
BLD
SKIN,
MUS,
MUS,
THYM,
BLD
No
rs927062 14:32,164,800 G/A 0.21 All invasive 0.94
(0.90–
0.97)
5.9 x
10−4
No Yes,
ARHGAP5
None GI No
SNP, single nucleotide polymorphism; alleles show minor/major; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; eQTL, expression quantitative
locus with p<0.05 in EOC tumors; histone marks and DNAse I hypersensitive sites from HaploReg v 4.1 indicating tissue types as defined therein; super enhancer
information based on the human super-enhancer database available at http://bioinfo.au.tsinghua.edu.cn/dbsuper/index.php; none of these SNPs had previous GWAS
associations with any phenotype based on the EBI GWAS catalog or resided within promoter histone marks; all SNPs are intronic to the gene indicated.
https://doi.org/10.1371/journal.pone.0197561.t001
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transcriptional coactivators in this tissue. As ARHGEF10L rs2256787 associated with endome-
trioid EOC risk, we were particularly interested in eQTLs in the 54 endometrioid patients;
however, there was no evidence of association between rs2256787 genotype and ARHGEF10L
expression in endometrioid EOC tumors or other tumor subtypes. In 312 invasive EOC
tumors, the G allele of AKAP6 rs927062 correlated with reduced expression of Rho GTPase
activating protein 5 (ARHGAP5), a GTPase ~150kb upstream of AKAP6 (β = -0.22, 95% CI:
-0.41 to -0.03, p = 6.6x10-3). Other unstudied variants may also be associated with expression
of ARHGAP5 (or may be more strongly associated than rs927062), thus future genome-wide
or pathway-based analysis of GTPase SNP-expression relationships are of great interest. In
other histology-specific eQTL analyses, none of the four variants tested were associated with
EOC tumor mRNA expression.
Conclusion
We investigated 322 SNPs in 88 genes encoding small GTP binding proteins of the Ras super-
family (Ras, Rho, Rab, Ral, Arf, and Ran) in germline DNA of over 17,000 EOC patients and
26,000 controls. The 88 genes were derived from G protein (guanine nucleotide-binding pro-
teins) signaling, Ras-GTPases, regulation of Rho GTPase protein signal transduction and acti-
vation of Rac GTPase activity. [18] Ras-GTPases are activated at the plasma membrane by
guanine nucleotide exchange factors (GEF) such as: son of sevenless homologs 1 and 2 (Dro-
sophila) (SOS-1 and SOS-2); Ras protein-specific guanine nucleotide-releasing factor 1
(GRF1); Rap guanine nucleotide exchange factor 1 (GRF2); and RasGEF domain family, mem-
bers 1A, 1B and 1C (RasGRF). They are inactivated by GTPase activating proteins (GAP)
which include RAS p21 protein activator (GTPase activating protein) 1 (p120RasGAP). GEF
factors are recruited to the plasma membrane by scaffold and adaptor complexes such as SHC/
Grb2 that associate with activated tyrosine kinase receptors (TKR).[19] These factors exchange
GTP for GDP on the Ras protein. The resulting GTP-Ras protein activates various down-
stream effectors such as MAP-kinase Raf-1 which activates the MEK/ERK gene regulation cas-
cade, a primary cell growth and anti-apoptosis pathway.[6] Ras-GTPases family members
regulate the action of other GTPase pathways involving Rap, Ral, Rac and Rho Ras-GTPase.
Ras-GTPases also regulate phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC)
activities.[5] Several of these genes are mutated in ovarian tumors.[20]
Overall, analysis at only one SNP yielded a p-value < 10−5: rs2256787 in ARHGEF10L
which was associated with 33% increased endometrioid EOC risk. Of note, the experiment-
wide error rate for this SNP, accounting for the initial overall set of 6103 candidate SNPs
equals 0.027 (Bonferroni-corrected p-value 4.5 x 10−6 x 6103); additionally accounting for six
case groups analyzed, this value increases to 0.16 (Bonferroni-corrected p-value 4.5 x 10−6 x
6103 x 6). However, as SNPs, as well as case groups, are not independent, simulation studies
are necessary to derive an empirical p-value. Another ARHGEF10L SNP, rs10788679, in
showed the smallest p-value in analysis of serous EOC and was the second-most strongly asso-
ciated SNP in all analyses. ARHGEF10L is a member of the RhoGEF family GEFs that activate
Rho GTPases.[21] The Rho branch of the Ras super family encompasses 20 genes in humans,
of which Rho, Rac and Cdc42 are the best characterized. Rho GTPases regulate the actin cyto-
skeleton and control changes in cell morphology and cell motility triggered by extracellular sti-
muli. Rho GTPases are regulated by GDP/GTP exchange factors and GAPs. Members of this
Fig 1. Association of rs2256787 in the ARHGEF10L gene with invasive endometrioid EOC risk by study site and combined. Squares represent the estimated per-
allele odds ratio (OR) and are proportional to sample size for each study; lines indicate its 95% confidence interval (CI); source indicates contributing study;[11] MAF,
control minor allele frequency; PVal, per-allele p-value adjusted for age, site, and principal components to account for residual differences in European ancestry.
https://doi.org/10.1371/journal.pone.0197561.g001
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subfamily are activated by specific GEFs and are involved in signal transduction. SNPs in this
gene are also associated with obesity[22] and cutaneous basal cell carcinoma.[23]
The SNP most associated with risk of invasive EOC was rs1955513 in the AKAP6 gene. This
gene is involved in overall G protein signaling. SNPs in this gene are also associated with neu-
rologic functioning [24] and anorexia.[25] Functionally, rs927062 in AKAP6 was associated
with expression of the Rho GTPase activating protein 5, ARHGAP5, also known as p190 Rho-
GAP, which negatively regulates RHO GTPases. The p190 RhoGAP gene contains a carboxy-
terminal domain that functions as a GAP for the Rho family GTPases. In addition to its Rho-
GAP domain, p190 contains an amino-terminal domain that contains sequence motifs found
in all known GTPases.
In conclusion, our study identified potentially functional genetic variants in small GTPase
genes that may have roles in EOC susceptibility. To interpret these associations, we suggest
consideration of effect sizes and directionality in the context of the sets of histotype-specific
analyses conducted; whether a more conservative or liberal statistical significance threshold is
applied, the small set of variants highlighted for detailed functional follow-up remain the
same. A limitation of this work is that nearby imputed variants were not examined and thus
other ungenotyped variants may be driving the reported associations. Nonetheless, four vari-
ants in two genes show promising associations that have not been reported previously but
point to known pathways that are mutated in ovarian tumors. The results of our investigation
suggest that further assessment of this important pathway is warranted in additional collec-
tions of densely genotyped EOC patients and controls.
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